Shufro Rose & Co. LLC purchased a new position in shares of AbbVie Inc (NYSE:ABBV) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,730 shares of the company’s stock, valued at approximately $243,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Hudock Capital Group LLC boosted its stake in shares of AbbVie by 109.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after purchasing an additional 806 shares in the last quarter. Ffcm LLC boosted its stake in shares of AbbVie by 167.2% in the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after purchasing an additional 963 shares in the last quarter. Bristlecone Advisors LLC acquired a new stake in shares of AbbVie in the 3rd quarter valued at $113,000. BDO Wealth Advisors LLC acquired a new stake in shares of AbbVie in the 2nd quarter valued at $115,000. Finally, Hershey Trust Co. acquired a new stake in shares of AbbVie in the 3rd quarter valued at $139,000. Hedge funds and other institutional investors own 69.54% of the company’s stock.

Several equities research analysts have recently commented on ABBV shares. Credit Suisse Group set a $135.00 target price on shares of AbbVie and gave the company a “hold” rating in a research note on Monday, January 29th. Societe Generale boosted their target price on shares of AbbVie in a research note on Tuesday, November 21st. Leerink Swann downgraded shares of AbbVie from an “outperform” rating to a “market perform” rating and set a $127.00 target price on the stock. in a research note on Monday, January 29th. BMO Capital Markets set a $84.00 target price on shares of AbbVie and gave the company a “hold” rating in a research note on Thursday, January 11th. Finally, Jefferies Group boosted their target price on shares of AbbVie from $115.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, January 4th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. AbbVie has an average rating of “Buy” and an average price target of $117.26.

In related news, Chairman Richard A. Gonzalez sold 218,193 shares of the company’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $94.01, for a total transaction of $20,512,323.93. Following the transaction, the chairman now owns 492,030 shares in the company, valued at approximately $46,255,740.30. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Laura J. Schumacher sold 145,510 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $96.71, for a total transaction of $14,072,272.10. The disclosure for this sale can be found here. In the last quarter, insiders have sold 450,743 shares of company stock worth $43,153,684. 0.23% of the stock is owned by corporate insiders.

AbbVie Inc (NYSE:ABBV) opened at $111.30 on Friday. The stock has a market cap of $177,682.67, a PE ratio of 33.83, a P/E/G ratio of 1.06 and a beta of 1.60. The company has a current ratio of 1.45, a quick ratio of 1.32 and a debt-to-equity ratio of 5.08. AbbVie Inc has a 52-week low of $60.15 and a 52-week high of $125.86.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, January 26th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.44 by $0.04. The business had revenue of $7.74 billion for the quarter, compared to the consensus estimate of $7.53 billion. AbbVie had a net margin of 18.82% and a return on equity of 152.78%. The firm’s quarterly revenue was up 13.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.20 EPS. analysts forecast that AbbVie Inc will post 7.46 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2018/02/11/shufro-rose-co-llc-purchases-new-position-in-abbvie-inc-abbv.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.